{"id":64014,"date":"2026-04-27T13:51:05","date_gmt":"2026-04-27T05:51:05","guid":{"rendered":"https:\/\/flcube.com\/?p=64014"},"modified":"2026-04-27T13:51:05","modified_gmt":"2026-04-27T05:51:05","slug":"nmpa-tightens-post-marketing-requirements-for-conditionally-approved-drugs-in-china-mandating-four-year-confirmatory-studies-and-annual-progress-reporting","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=64014","title":{"rendered":"NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting"},"content":{"rendered":"\n<p>China\u2019s <strong>National Medical Products Administration (NMPA)<\/strong> has issued a new regulatory framework clarifying post-approval obligations for <strong>conditionally approved drugs<\/strong>, requiring marketing authorization holders (MAHs) to complete <strong>confirmatory studies within four years<\/strong> of product launch and submit <strong>annual progress reports<\/strong> to regulators.<\/p>\n\n\n\n<p>The guidance, titled <em>\u201cAnnouncement on the Review and Approval Procedures for Drug Conditional Approval Applications,\u201d<\/em> released late last week, establishes a standardized timeline and reporting structure aimed at accelerating evidence generation while ensuring patient safety.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-key-regulatory-provisions\">Key Regulatory Provisions<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Requirement<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Confirmatory Study Deadline<\/strong><\/td><td>Must be completed <strong>within 4 years<\/strong> of marketing initiation<\/td><\/tr><tr><td><strong>Annual Reporting<\/strong><\/td><td>MAH must submit study progress + Periodic Safety Update Report (PSUR) to <strong>CDE<\/strong> yearly<\/td><\/tr><tr><td><strong>Local Oversight<\/strong><\/td><td>Copy of progress report simultaneously filed with <strong>provincial medical products authority<\/strong><\/td><\/tr><tr><td><strong>Certificate Validity<\/strong><\/td><td>Set at <strong>1 year beyond<\/strong> the agreed confirmatory study completion date<\/td><\/tr><tr><td><strong>Conversion to Regular Approval<\/strong><\/td><td>Triggers validity period reset per defined rules (see below)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-registration-certificate-validity-rules\">Drug Registration Certificate Validity Rules<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-scenario-1-all-indications-initially-conditional\">Scenario 1: All Indications Initially Conditional<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Upon first indication\u2019s conversion to <strong>regular approval<\/strong>, a <strong>new 5-year certificate<\/strong> is issued (effective from regular approval date).<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-scenario-2-mixed-approval-status-some-regular-some-conditional\">Scenario 2: Mixed Approval Status (Some Regular, Some Conditional)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>When additional conditional indications convert to regular approval, their validity aligns with the <strong>existing regularly approved indication\u2019s expiry date<\/strong>.<\/li>\n<\/ul>\n\n\n\n<p>This tiered approach ensures administrative consistency while incentivizing timely data submission.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications-for-pharma-companies\">Strategic Implications for Pharma Companies<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Timeline Certainty<\/strong>: The <strong>4-year window<\/strong> provides clarity for clinical development planning, replacing ad-hoc expectations.<\/li>\n\n\n\n<li><strong>Compliance Burden<\/strong>: Dual reporting (central CDE + provincial agency) increases operational complexity, particularly for multinational MAHs with domestic responsible parties.<\/li>\n\n\n\n<li><strong>Portfolio Management<\/strong>: Companies must prioritize resources for post-marketing studies to avoid certificate expiration or market withdrawal.<\/li>\n\n\n\n<li><strong>Investor Impact<\/strong>: Delays in confirmatory data could trigger regulatory non-compliance flags, affecting revenue sustainability in China\u2014a market representing >20% of global pharma growth.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-context-amp-enforcement-outlook\">Context &amp; Enforcement Outlook<\/h2>\n\n\n\n<p>The move aligns with NMPA\u2019s broader push to harmonize with international standards (e.g., FDA accelerated approval, EMA conditional marketing authorization) while maintaining China-specific oversight mechanisms. Non-compliance may result in <strong>suspension of sales<\/strong> or <strong>non-renewal of registration certificates<\/strong>, posing material commercial risk.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief summarizes newly issued regulatory requirements. Implementation timelines and enforcement rigor may evolve based on industry feedback and pilot program outcomes.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China\u2019s National Medical Products Administration (NMPA) has issued a new regulatory framework clarifying post-approval obligations&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[4],"tags":[],"class_list":["post-64014","post","type-post","status-publish","format-standard","hentry","category-policy-regulatory"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China\u2019s National Medical Products Administration (NMPA) has issued a new regulatory framework clarifying post-approval obligations for conditionally approved drugs, requiring marketing authorization holders (MAHs) to complete confirmatory studies within four years of product launch and submit annual progress reports to regulators.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=64014\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting\" \/>\n<meta property=\"og:description\" content=\"China\u2019s National Medical Products Administration (NMPA) has issued a new regulatory framework clarifying post-approval obligations for conditionally approved drugs, requiring marketing authorization holders (MAHs) to complete confirmatory studies within four years of product launch and submit annual progress reports to regulators.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=64014\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-27T05:51:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64014#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64014\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting\",\"datePublished\":\"2026-04-27T05:51:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64014\"},\"wordCount\":385,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"articleSection\":[\"Policy \\\/ Regulatory\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64014#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64014\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=64014\",\"name\":\"NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-27T05:51:05+00:00\",\"description\":\"China\u2019s National Medical Products Administration (NMPA) has issued a new regulatory framework clarifying post-approval obligations for conditionally approved drugs, requiring marketing authorization holders (MAHs) to complete confirmatory studies within four years of product launch and submit annual progress reports to regulators.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64014#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64014\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64014#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting - Insight, China&#039;s Pharmaceutical Industry","description":"China\u2019s National Medical Products Administration (NMPA) has issued a new regulatory framework clarifying post-approval obligations for conditionally approved drugs, requiring marketing authorization holders (MAHs) to complete confirmatory studies within four years of product launch and submit annual progress reports to regulators.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=64014","og_locale":"en_US","og_type":"article","og_title":"NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting","og_description":"China\u2019s National Medical Products Administration (NMPA) has issued a new regulatory framework clarifying post-approval obligations for conditionally approved drugs, requiring marketing authorization holders (MAHs) to complete confirmatory studies within four years of product launch and submit annual progress reports to regulators.","og_url":"https:\/\/flcube.com\/?p=64014","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-27T05:51:05+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=64014#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=64014"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting","datePublished":"2026-04-27T05:51:05+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=64014"},"wordCount":385,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"articleSection":["Policy \/ Regulatory"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=64014#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=64014","url":"https:\/\/flcube.com\/?p=64014","name":"NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-27T05:51:05+00:00","description":"China\u2019s National Medical Products Administration (NMPA) has issued a new regulatory framework clarifying post-approval obligations for conditionally approved drugs, requiring marketing authorization holders (MAHs) to complete confirmatory studies within four years of product launch and submit annual progress reports to regulators.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=64014#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=64014"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=64014#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64014","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=64014"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64014\/revisions"}],"predecessor-version":[{"id":64015,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64014\/revisions\/64015"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=64014"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=64014"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=64014"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}